BP101 for Adults With Female Sexual Dysfunction

PHASE3CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

November 26, 2018

Study Completion Date

January 23, 2019

Conditions
Hypoactive Sexual Desire DisorderFemale Sexual DysfunctionSexual Desire Disorder
Interventions
DRUG

BP101

Investigational product BP101, nasal spray

DRUG

Placebo

Placebo to Investigational product BP101, nasal spray

Trial Locations (20)

Unknown

Алтайский государственный медицинский университет, Barnaul

Kazan State Medical University, Kazan'

Kuban State Medical University, Krasnodar

Central Clinical Hospital of the Russian Academy of Sciences, Moscow

N.A. Alexeev Moscow Psychiatric Clinical Hospital #1, Moscow

National Medical Research Center of Obstetrics, Gynecology and Perinatology, Moscow

National Medical Research Center of Psychiatry and Addiction named after V.P. Serbsky, Moscow

Clinical Psychiatry Hospital №1, Nizhny Novgorod

Orenburg Regional Clinical Psychiatric Hospital No. 2, Orenburg

City psychiatric hospital №7 named after academician I.P. Pavlov, Saint Petersburg

Doctor SAN Ltd., Saint Petersburg

Leningrad Regional Narcological Dispensary, Saint Petersburg

OrKli Hospital LLC, Saint Petersburg

Research center Eco-Safety LLC, Saint Petersburg

Samara Psychiatric Hospital, Samara

Regional Clinical Psychiatric Hospital of St. Sofia, Saratov

Engels Psycyatric hospital, Saratovskaya

"Clinic Hundred Years", Tomsk

Bashkir State Medical University, Ufa

Yaroslavl Regional Clinical Psychiatric Hospital, Yaroslavl

All Listed Sponsors
lead

Ivix LLX

INDUSTRY

NCT03463707 - BP101 for Adults With Female Sexual Dysfunction | Biotech Hunter | Biotech Hunter